-
公开(公告)号:EP4110764A1
公开(公告)日:2023-01-04
申请号:EP21713803.1
申请日:2021-02-26
IPC分类号: C07D235/30 , C07D401/12 , C07D403/12 , C07D471/04 , C07D403/14 , C07D405/12 , A61P29/00 , A61K31/4168 , C07D413/14
-
公开(公告)号:EP3952990A1
公开(公告)日:2022-02-16
申请号:EP20722177.1
申请日:2020-04-08
申请人: Mitobridge, Inc.
发明人: BIDDLE, Margaret , KLUGE, Arthur , SASMAL, Sanjita , LAGU, Bharat , WU, Xinyuan , OGIYAMA, Takashi , BELL, Eric
IPC分类号: A61P3/10 , A61K31/4184 , A61P5/14 , A61P7/00 , A61P9/00 , A61P17/00 , A61P21/00 , A61P25/28 , A61P35/00 , C07D235/30 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D513/04
-
公开(公告)号:EP3672953B1
公开(公告)日:2021-07-28
申请号:EP18755828.3
申请日:2018-08-22
发明人: SØRENSEN, Ulrik , METE, Antonio
IPC分类号: C07D403/12 , C07D401/12 , C07D235/30 , C07D405/12 , C07D413/12 , A61P9/06 , A61K31/4184
-
公开(公告)号:EP3718569A1
公开(公告)日:2020-10-07
申请号:EP20159132.8
申请日:2016-05-23
发明人: WANG, Tong , GATELY, Stephen , GONZALES, Paul
IPC分类号: A61K39/395 , C07K16/28 , A61K31/4184 , C07D235/30 , C07D401/04 , C07D403/04 , A61P35/00 , A61P35/04
摘要: The present invention describes a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
-
公开(公告)号:EP3668841A1
公开(公告)日:2020-06-24
申请号:EP18750455.0
申请日:2018-08-13
申请人: Acesion Pharma ApS
IPC分类号: C07D235/30 , A61P9/00 , A61K31/4184
-
6.
公开(公告)号:EP3570832A2
公开(公告)日:2019-11-27
申请号:EP18741114.5
申请日:2018-01-16
发明人: LEWIS, Richard, T. , HAMILTON, Matthew , JONES, Philip , PETROCCHI, Alessia , REYNA, Naphtali , CROSS, Jason , HAN, Michele , SOTH, Michael , MCAFOOS, Timothy , TREMBLAY, Martin
IPC分类号: A61K31/41 , A61K31/433 , C07D235/30
-
7.
公开(公告)号:EP3394052A1
公开(公告)日:2018-10-31
申请号:EP16797555.6
申请日:2016-11-16
申请人: Kancera AB
发明人: HAMMER, Kristin , JÖNSSON, Mattias , KRÜGER, Lars
IPC分类号: C07D413/14 , C07D333/54 , C07D401/04 , C07D235/30 , C07D409/04 , C07D413/04 , C07D413/10 , C07D417/04 , C07D471/04 , C07D487/04 , C07D263/57 , C07D491/04 , C07D495/04 , C07D498/04 , C07D209/08 , C07D277/66 , C07D307/79 , A61K31/4184 , A61K31/423 , A61K31/428
CPC分类号: C07D263/57 , C07D209/08 , C07D235/30 , C07D263/58 , C07D277/64 , C07D277/66 , C07D307/79 , C07D333/54 , C07D401/04 , C07D409/04 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D498/04
摘要: A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
-
公开(公告)号:EP3353151A1
公开(公告)日:2018-08-01
申请号:EP16774993.6
申请日:2016-09-22
发明人: CHONG, Pek Yoke , DE LA ROSA, Martha , DICKSON, Hamilton , KAZMIERSKI, Wieslaw Mieczyslaw , SAMANO, Vicente , TAI, Vincent Wing-Fai
IPC分类号: C07D213/74 , C07D309/14 , C07D333/20 , C07D235/30 , C07D239/42 , C07D241/20 , C07D253/06 , C07D263/48 , C07D263/58 , C07D277/82 , C07D285/00 , C07D307/66 , A61K31/44 , A61K31/433 , A61K31/421 , A61K31/426 , A61P31/18
CPC分类号: C07D263/58 , C07D213/74 , C07D235/30 , C07D239/42 , C07D241/20 , C07D253/06 , C07D263/48 , C07D277/82 , C07D285/00 , C07D307/66 , C07D309/14 , C07D333/20
摘要: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.
-
公开(公告)号:EP3305759A1
公开(公告)日:2018-04-11
申请号:EP16803508.7
申请日:2016-06-03
发明人: IHORI, Yoichi , INOUE, Shuuji , SHIBAYAMA, Kotaro , KANG, Chang-Kyung , SHIINOKI, Yasuyuki , KAMADA, Takuya , NAITO, Hiroaki , NISHIMURA, Satoshi
IPC分类号: C07C279/12 , A01N43/50 , A01N43/52 , A01N47/12 , A01N47/44 , A01N51/00 , A01P3/00 , C07C279/08 , C07C279/24 , C07D213/64 , C07D233/46 , C07D233/52 , C07D233/88 , C07D235/30 , C07D237/14 , C07D277/28 , C07D307/81 , C07D333/22 , C07D401/14
CPC分类号: A01N47/40 , A01N43/50 , A01N43/52 , A01N47/12 , A01N47/28 , A01N47/44 , A01N51/00 , C07C279/08 , C07C279/12 , C07C279/24 , C07C335/02 , C07D213/64 , C07D213/78 , C07D233/46 , C07D233/48 , C07D233/52 , C07D233/88 , C07D235/30 , C07D237/14 , C07D237/24 , C07D239/06 , C07D243/04 , C07D277/28 , C07D277/56 , C07D307/81 , C07D333/22 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04
摘要: A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R 7 -R 9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q 1 and Q 2 independently represents a single bond or the like; each of A 1 and A 2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R 1 -R 6 independently represents a hydrogen atom or the like.)
摘要翻译: 具有优异杀真菌活性的新型胍化合物由式[I]表示。 (式中,Y表示由式[II]表示的二价基团(其中R7-R9各自独立地表示氢原子等)等; X和Z各自独立地表示未取代或取代的亚烷基或 每个Q1和Q2独立地表示单键等; A1和A2各自独立地表示未取代或取代的二价杂环化合物残基等;并且每个R1-R6独立地表示氢原子等 。)
-
10.
公开(公告)号:EP3297674A1
公开(公告)日:2018-03-28
申请号:EP16800623.7
申请日:2016-05-23
发明人: WANG, Tong , GATELY, Stephen , GONZALES, Paul
IPC分类号: A61K39/395 , A61K31/4184 , C07D235/30 , C07D401/04 , C07D403/04
CPC分类号: A61K39/3955 , A61K31/4184 , A61K31/7068 , A61K45/06 , A61K47/18 , A61K47/22 , A61K47/26 , A61K2039/507 , A61K2300/00 , A61P35/00 , C07D235/30 , C07D401/04 , C07D403/04 , C07K16/2818 , C07K2317/76
摘要: The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, or a DNA demethylating agent and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
-
-
-
-
-
-
-
-
-